Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.54M | -3.42M | -2.69M | -2.57M | -2.33M |
| Total Depreciation and Amortization | 171.60K | 165.60K | 136.30K | 130.30K | 148.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -834.00K | -804.60K | 132.00K | 126.30K | -335.10K |
| Change in Net Operating Assets | -156.40K | -150.90K | 452.20K | 432.40K | -384.10K |
| Cash from Operations | -4.36M | -4.21M | -1.97M | -1.88M | -2.91M |
| Capital Expenditure | -3.20K | -3.10K | -10.30K | -9.80K | -31.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 149.50K | 144.20K | 225.50K | 215.60K | 9.19M |
| Cash from Investing | 146.30K | 141.10K | 215.30K | 205.80K | 9.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -105.00K | -105.00K | -195.50K | -195.50K | -- |
| Issuance of Common Stock | 11.00K | 11.00K | 6.71M | 6.71M | 4.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -119.10K | -114.90K | 7.86M | 7.52M | 4.90K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.33M | -4.18M | 6.11M | 5.84M | 6.26M |